While the authors suggest therapeutics targeting shared pathways could benefit genotype-stratified patient groups, the practical implementation of this precision medicine approach remains undefined. This gap affects clinical translation of genetic discoveries. Gap type: open_question Source paper: Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. (2018, The Lancet. Neurology, PMID:29154141)
Landscape Summary: How can genotype-stratified therapeutics targeting common ALS pathways be effectively implemented? is a 0.76 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
How can genotype-stratified therapeutics targeting common ALS pathways be effectively implemented? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: